Biosimilar therapies in inflammatory bowel disease: should we care about patient profile?

Expert Rev Clin Immunol. 2016;12(4):361-3. doi: 10.1586/1744666X.2016.1141050. Epub 2016 Feb 8.

Authors

Gionata Fiorino¹, Maria Fazio², Silvio Danese³

Affiliations

¹ a IBD Center, Department of Gastroenterology , Humanitas Research Hospital , Rozzano, Milan , Italy.
² b Pharmacy , Humanitas Research Hospital , Rozzano, Milan , Italy.
³ c Department of Biomedical Sciences , Humanitas University , Rozzano, Milan , Italy.

PMID: 26752540
DOI: 10.1586/1744666X.2016.1141050

No abstract available

Publication types

Editorial

MeSH terms

Biosimilar Pharmaceuticals / economics
Biosimilar Pharmaceuticals / therapeutic use*
Child
Cost of Illness
Humans
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / economics
Infliximab / economics
Infliximab / therapeutic use*
Patient-Centered Care

Substances

Biosimilar Pharmaceuticals
Infliximab